In particular, it has been reported previously that activation of IGF1R signaling is implicated in NSCLC differentiation and survival in patients, conferring acquired resistance to Osimertinib in NSCLC containing the EGFR T790M mutation [43]. This evidence concerns the gene IGF1R and non-small cell lung carcinoma.